Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Trial Profile

Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms IMIDAS
  • Most Recent Events

    • 06 Dec 2016 Results assessing the efficacy and safety of dasatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 27 Oct 2015 Results published in the European Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top